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shown to reduce AML relapse for patients in CR1. Cyclophos-
phamide in the conditioning is suspected of contributing to
signiﬁcant toxicity. Preliminary work with high doses of TBI
(16Gy), without cyclophosphamide, followed by an HLA
matched related or unrelated donor (MRD or MUD)-alloHCT
has resulted in long-term remissions in 2 out of 4 patients.
Based on these encouraging results we initiated and report on
the preliminary results of a phase 2 study of single agent
extended dose TBI (ED-TBI) (18Gy).
Methods: Patients (18-60 years old) with rAML and an HLA
MRD or MUD received an alloHCT after ED-TBI, 2.25Gy BID
(days -4 to -1) x 8 fractions (total 18Gy). Donor cells were
infused on day 0. Tacrolimus (day -3) and mycophenolate
mofetil (MMF) (day 1) were used for graft vs. host disease
(GVHD) prophylaxis. Toxicity was measured using the CTCAE
v.4 and the LENT-SOMA scales. The primary end point was
treatment related mortality (TRM). Secondary endpoints
included: engraftment, morbidity/mortality at 30, 100 and
>180 days, incidence of GVHD, relapse rate and one year
progression-free (PFS) and OS.
Results: Patients: Five patients have been enrolled. One pa-
tient had rAML following two induction attempts. Another
patient had rAML (secondary) after one induction attempt
and three had relapsed (<6months) rAML. All had persistent
leukemia at the start of ED-TBI, with 4 out of 5 having > 50%
blast cells in the marrow.
Toxicity: <30 days, 2 patients had grade 3 mucositis. Two
patients required parenteral feeding. One patient experienced
reversible veno-occlusive disease. All patients developed
diarrhea. Two patients suffered from grade 3 dehydration,
requiring prolonged intravenous hydration (days 37-107).
Engraftment: Neutrophil engraftment occurred between
days 15-25 and the patients were discharged from the hos-
pital between days 19-30.
GVHD: Immunosuppression was completely tapered at
day 101 in 1 patient. One patient continues to taper off at day
217, due to persistent chronic GVHD (cGVHD) and 3 did not
complete tapering before relapse. Acute GVHD occurred in 1
patient <day 30, treated with prednisone. cGVHD occurred
in all patients >day 100, involving the GI tract (n¼2) and
liver (n¼2). One patient has persistent cGVHD beyond 4
months involving the mouth and lungs.
Response: Of the 4 patients who had circulating blast
cells, all were cleared by day 1. Two patients are in contin-
uous CR on days 217 and 338. Three patients have relapsed at
days 96, 110 and 139 and died on days 106, 145 and 257,
respectively.
Conclusion: rAML is controlled by ED-TBI followed by an
alloHCT. The toxicity of ED-TBI is acceptable and comparable
to other alloHCT conditioning regimens. Safety and efﬁcacy
are continuing to be assessed with a goal to recruit 20
patients.225
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The nucleoside analogs clofarabine (Clo) and ﬂudarabine
(Flu), together with the DNA alkylating agent busulfan (Bu),
are commonly used as part of the pre-transplant conditioningregimen in allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT). The multikinase inhibitor sorafenib
(Sor) has clinical activity in FLT3-ITD-positive acute myeloid
leukemia (AML). We previously reported that a combination
of [Bu+Clo+Flu] has a synergistic cytotoxicity in AML cells.We
now hypothesized that Sor, if combined with [Bu+Clo+Flu],
will further enhance this cytotoxicity. We exposed the FLT3-
ITD-mutated AML cell line MV4-11 to low concentrations of
Bu (1 mg/ml), Clo (10 nM), Flu (2.5 mM) and Sor (1 nM) alone or
in various combinations. Exposure of the cells to Bu, Clo, Flu
or Sor alone, or to two-drug combinations [Bu+Clo], [Bu+Flu]
and [Clo+Flu], did not signiﬁcantly affect cell proliferation or
apoptosis relative to control cells. The combination of
[Bu+Clo+Flu] resulted in 20% inhibition of cell proliferation
and demonstrated 10% increase in apoptosis. Addition of Sor
to the [Bu+Clo+Flu] mixture further enhanced the inhibition
of proliferation by 60%, and increased apoptosis to 50%, sug-
gesting synergistic cytotoxicity. Biochemical analyses suggest
that this cytotoxicity may be attributed to (1) activated DNA-
damage response (2) histone 3modiﬁcations, (3) inhibition of
different kinases, and (4) activation of the intrinsic apoptosis
pathway. The phosphorylation of kinases, including FLT3,
MEK and AKT, was signiﬁcantly inhibited when cells were
exposed to [Bu+Clo+Flu+Sor]. FLT3-ITD-activated STAT5 and
its target gene Pim 2, a serine threonine kinase, were both
down-regulated when cells were exposed to Sor alone,
[Bu+Clo+Flu] and [Bu+Clo+Flu+Sor]. The level of the pro-
apoptotic protein PUMA increased, while the pro-survival
proteins MCL-1 and Bcl-xL were down-regulated when cells
were exposed to the four-drug combination. The levels of
phosphorylated and total P53 increased in the mitochondria
when cells were exposed to [Bu+Clo+Flu] or [Bu+Clo+-
Flu+Sor]. The changes in the levels of these proteins involved
in mitochondrial control of apoptosis may consequently
cause mitochondrial outer membrane permeabilization
(MOMP). The mitochondrial membrane potential (MMP), a
marker of MOMP, decreased by 20% and 60% when cells were
exposed to [Bu+Clo+Flu] and [Bu+Clo+Flu+Sor], respectively.
This drug-mediated decrease in MMP may have caused
leakage of cytochrome c, SMAC/DIABLO and AIF from the
mitochondria to the cytoplasm and/or nucleus, leading to
caspase activation, nuclear fragmentation and cell death.
These results provide amechanistic basis for investigating the
addition of sorafenib in future clinical trials of (double)
nucleoside analog-busulfan combinations in pre-transplant
conditioning therapy for patients undergoing allo-HSCT for
FLT3-ITD positive AML.LYMPHOMA/MULTIPLE MYELOMA226
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Mature T-Cell lymphoma (PTCL) is a heterogeneous group of
malignancies characterized by a poor outcome when treated
with antracycline-based chemotherapy regimens. High-dose
chemotherapy with autologous transplantation (auto-HCT)
has emerged as a commonly used strategy for patients in ﬁrst
remission or at the time of ﬁrst chemosensitive relapse.
However, data are limited and the role of autografting re-
mains undeﬁned. Here, we present a retrospective analysis of
67 patients with PTCL who underwent autoHCT at our center
between January 2000 and December 2011. Histological
subtypes included anaplastic large cell lymphoma (ALCL,
n¼27, 40.3%), peripheral T-cell lymphoma not other speciﬁed
(PTCL-NOS, n¼25, 37.3%), angioimmunoblastic T-cell lym-
phoma (AITL, n¼7, 10.4%), other (n¼8, 11.9%).
Median age at the time of auto-HCT was 52 years (22-75),
median time from diagnosis to HCT was 10 months (6-193)
and median follow up for surviving patients was 38 months
(6-136). Forty-one (61%) were male. At diagnosis, 52 (77%)
had stage III/IV, 39 (58%) had at least one extranodal site of
disease, 18 (27%) had intermediate-high or high-risk by in-
ternational prognostic index (IPI) and 16 (24%) had inter-
mediate-high or high-risk by PTCL prognostic index (PIT). At
transplantation, 32 (48%) had received 1 line of therapy and
35 (52%) had received 2 or more. Thirty-six patients (54%)
were in ﬁrst complete remission (CR1) and 62 (92%) had
shown sensitivity tomost recent therapy. BEAM (carmustine,
etoposide, cytarabine and melphalan) was used as condi-
tioning regimen in 52 patients (78%) and no patient received
a radiation based regimen.
Five-year overall survival (OS) was 65%. In univariate anal-
ysis, OS was associated with number of lines of therapy [>1
vs. 1, (Hazard ratio (HR)¼3.604; 95% CI: 1.335, 9.725;
p¼0.011)] and remission status [(CR1 vs. other (HR¼0.303,
95% CI: 0.124, 0.741; p¼0.009); (CR vs. other (HR¼ 0.223, 95%
CI: 0.096, 0.518; p¼0.0005)]. PFS was associated with age
[age >50 vs. 50 (HR¼2.308, 95% CI: 1.01, 5.26, p¼0.047)]
and remission status [CR1 vs. other (HR¼ 0.396, 95% CI:
0.185, 0.849, p¼0.017), CR vs. other (HR¼0.246, 95% CI: 0.115,
0.525, p<0.001)]. Only 4 patients died of causes other than
relapse.
In conclusion, patients with PTCL who underwent an auto-
HCT early in the course of the disease appear to beneﬁt the
most, achieving durable remissions. Disease relapse remains
the most common cause of failure. Maintenance strategieswith novel therapies remain a reasonable research question
to address in large prospective clinical trials.
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Background: Proteasome inhibitors (PI) impair the fanconi/
BRCApathwayofDNA repair and increaseDNA fragmentation
and apoptosis induced by alkylating agents in in vitro MM
cells. We hypothesized that combining carﬁlzomib, a second
generation PI, with melphalanwould result in more effective
anti myeloma activity. We herein performed a phase 1
study to identify the maximal tolerated dose (MTD) of car-
ﬁlzomib used in combinationwithmelphalan (200mg/m2) as
conditioning regimen prior to AHSCT for patients with
advanced MM.
Methods: Phase 1, multicentric, dose escalation trial with
traditional 3+3 design. Inclusion criteria required symp-
tomatic MM, relapse after at least one line of therapy (prior
AHSCT allowed), evaluable disease and at least minimal
response (MR) after the most recent salvage regimen. Sub-
jects were required to have at least 2 x 106 CD34+ cells/kg in
storage + 2 x 106 CD34+ cells/kg as “back up”. Treatment
consisted of two doses of carﬁlzomib administered IV over
30 minutes on days -3 and -2. The latter dose was adminis-
tered one hour prior to melphalan (Figure 1). Carﬁlzomib
dose consisted of 20(day-3)/27 (day -2) mg/m2 (cohort 0),
27/27 (cohort 1), 27/36 (cohort 2), 27/45 (cohort 3) and 27/56
mg/m2 (cohort 4). Dose limiting toxicities (DLT, non-hema-
tologic grade 4 and selected grade 3 toxicities) were evalu-
ated during the ﬁrst 30 days after AHSCT. Disease response
was assessed 100 days after AHSCT.
Results: Fifteen subjects were accrued in cohorts 0-4. At the
time of this report 14/15 subjects have completed the DLT
